The definitive benchmark for gene editing dealmaking
Gene editing partnering is driven by advanced platform technologies and rapid innovation, with deal structures reflecting access to proprietary tools, intellectual property, and next-generation therapeutic capabilities.This report provides a comprehensive and structured analysis of 410 gene editing collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how gene editing deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by platform type, application, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a highly innovative and IP-driven landscape
- Full visibility into deal structure and execution
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark platform and advanced technology transactions
- Prepare for negotiations with well-defined market context
- Evaluate licensing, co-development, and technology partnerships
- Support internal strategy with robust, defensible data
What’s included?
- 410 gene editing collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, platform, and application)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for gene editing dealmaking
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Gene editing dealmaking by technology type
Chapter 2 - Trends in gene editing dealmaking
Chapter 3 - Leading gene editing deals
Chapter 4 - Most active gene editing dealmakers
Chapter 5 - Gene editing contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- 4D Molecular Therapeutics
- 221b Foundation
- Abbvie
- Accelerated Biosciences
- Acrobat Genomics
- Acuitas Therapeutics
- Adaptimmune
- Adicet Bio
- Advanced Biological Innovation and Manufacturing
- Adverum Biotechnologies
- Aelian Biotechnology
- Affini-T Therapeutics
- Agilent Technologies
- Agribody Technologies
- Albany Molecular Research
- ALBOT Technologies
- Alcyone Lifesciences
- Aldevron
- Algen Biotechnologies
- AlgenScribe
- Allele Biotechnology and Pharmaceuticals
- Allergan
- Allogene Therapeutics
- Amazon Web Services
- American Skin Association
- Amfora
- AmplyCell
- Anagenesis Biotechnologies
- Ankarys Therapeutics
- Anocca AB
- Applied Biological Materials
- Applied StemCell
- Arbor Biotechnologies
- Arbutus
- Arctoris
- Artisan Bio
- ASC Therapeutics
- Asklepios Biopharmaceutical
- Astellas Pharma
- AstraZeneca
- ATUM
- Aurigene Pharmaceutical Services
- Avectas
- Avellino Labs
- Avita Therapeutics
- Axcelead Drug Discovery Partners
- Axxam
- B-MoGen Biotechnologies
- BASF
- Batavia Biosciences
- Baxalta
- Bayer
- Bayer CropScience
- Beam Therapeutics
- Ben-Gurion University
- Benson Hill Biosystems
- Berkeley Lights
- Beth Israel Deaconess Medical Center
- Bill and Melinda Gates Foundation
- Binx Health
- Bio-Techne
- BioCentriq
- Biogen
- Bioheuris
- Biomedical Advanced Research and Development Authority
- Bioneer
- Bluebird Bio
- BlueRock Therapeutics
- Boehringer Ingelheim
- Bone Therapeutics
- BRAIN Biotech
- BrainXell
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Broad Clinical Labs
- Broad Institute
- Broken String Biosciences
- Brooklyn ImmunoTherapeutics
- C4X Discovery
- Cabaletta Bio
- California Institute for Regenerative Medicine
- California Institute of Technology
- Calyxt
- CANbridge Pharmaceuticals
- Cancer Research UK
- Canopy Biosciences
- Capsida Biotherapeutics
- Caravan Biologix
- CARB-X
- Caribou Biosciences
- Casebia Therapeutics
- CasZyme
- Catalent
- Catamaran Bio
- Cellecta
- Cellectis
- Cellibre
- Cellipont Bioservices
- Cellistic
- Cell Microsystems
- Cellular Engineering Technologies
- Center for Human Genetics and Laboratory Medicine
- Central Institute for Experimental Animals
- Cepheid
- CGA 369
- Charles River Laboratories
- CHDI Foundation
- Chiesi Farmaceutici
- China Agricultural University
- Chroma Medicine
- CHUM Research Centre
- CIC nanoGUNE
- Cimeio Therapeutics
- Cirena
- City of Hope
- Coastar Therapeutics
- Cocrystal Pharma
- Codiak BioSciences
- Colors Farm
- Columbia University
- Columbia University Medical Center
- Corteva Agriscience
- Cosmo Bio
- CRISPR Therapeutics
- Crown Bioscience
- Cumming
- Curia
- Cyrus Biotechnology
- CytoLynx Therapeutics
- Cytosurge
- CYTOVIA Therapeutics
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- Dartmouth-Hitchcock Medical Center
- DefiniGEN
- Demeetra AgBio
- Department of Defense
- Desktop Genetics
- Dow AgroSciences
- Duke University
- DuPont
- DuPont Pioneer
- Dyadic International
- EdiGene
- Editas Medicine
- eGenesis
- Element Biosciences
- ElevateBio
- Eligo Bioscience
- Eli Lilly
- EMBRAPA
- EmendoBio
- Emendo Biotherapeutics
- Emory University
- ERS Genomics
- Evogene
- Evolva
- Evotec
- Evox Therapeutics
- Excision BioTherapeutics
- Exonics Therapeutics
- Factor Bioscience
- FASMAC
- Food and Drug Administration (FDA)
- Francis Crick Institute
- Frederick National Laboratory For Cancer Research
- Friedreichs Ataxia Research Alliance
- Fujifilm
- Fujifilm Diosynth Biotechnologies
- Fulcrum Therapeutics
- FuturaGene
- G+FLAS Life Sciences
- GDM Seeds
- Geisel School of Medicine at Dartmouth
- GEMoaB
- GenAhead Bio
- GenEdit
- GenEditBio
- Genentech
- GeneThera
- Genetic Information Research Institute
- Genevant Sciences
- GenKOre
- genOway
- GenScript Biotech
- Gensus
- Genus
- GenVec
- Gilead Sciences
- Ginkgo BioWorks
- Goethe University Frankfurt
- Great Ormond Street Hospital (GOSH)
- Greenlight Biosciences
- GSK
- GSK Consumer Healthcare
- Harpe Bioherbicide Solutions
- Harvard Medical School
- Harvard Stem Cell Institute
- Harvard University
- HebeCell
- Helen F Graham Cancer Center
- Helmholtz Zentrum Munchen
- Hillstream BioPharma
- Homology Medicines
- Horizon Discovery
- Horizon Pharma plc
- HuidaGene Therapeutics
- Humacyte
- Humanigen
- Hunterian Medicine
- IBM Watson Health
- IDbyDNA
- IDEAYA Biosciences
- iECURE
- Illumina
- Immatics Biotechnologies
- ImmunoChina Pharmaceuticals
- Immusoft
- Implant Therapeutics
- InnoBation
- Innovative Genomics Initiative (IGI)
- Inscripta
- Integrated DNA Technologies
- Integra Therapeutics
- Intellia Therapeutics
- Ionis Pharmaceuticals
- Iovance Biotherapeutics
- IRBM
- Israeli National Authority for Technological Innovation
- Jackson Laboratory
- Janssen Pharmaceuticals
- Japan SLC
- Johns Hopkins University
- Jorna Therapeutics
- Jumpcode Genomics
- Kadimastem
- Kamau Therapeutics
- Kantonsspital St. Gallen
- Keck Graduate Institute of Applied Life Sciences
- Kiromic Biopharma
- Kite Pharma
- Knudra Transgenics
- KOMO Biosciences
- KromaTiD
- KSQ Therapeutics
- Kytopen
- Kyverna Therapeutics
- Lepton Pharmaceuticals
- Les Laboratoires Servier
- Leveragen
- Life Edit Therapeutics
- Locus Biosciences
- LogicBio Therapeutics
- LogicInk
- Logomix
- Lonza
- Ludwig Institute for Cancer Research
- Mammoth Biosciences
- Marina Biotech
- Massachusetts Eye and Ear Infirmary
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- MaSTherCell
- Max-Delbruck Center for Molecular Medicine
- Maxcyte
- Mayo Clinic
- Medicines Discovery Catapult
- MEDiC Life Sciences
- MediGene
- Meiogenix
- Mekonos
- Merck and Co
- Merck KGaA
- Metagenomi
- MilliporeSigma
- Mission Bio
- Modalis Therapeutics
- Moderna
- Molecular Templates
- Monsanto
- Moonlight Bio
- Muscular Dystrophy Association
- Mustang Bio
- Myeloid Therapeutics
- Nanjing Darwingenetech
- NanoString Technologies
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Kidney Foundation
- National Organization for Rare Disorders
- Navega Therapeutics
- Ncardia
- Neon Therapeutics
- Netherlands Cancer Institute
- New England Biolabs
- New York University School of Medicine
- Nippon Gene
- Nkarta Therapeutics
- NLS Pharmaceutics
- NMI Natural and Medical Sciences Institute
- Nomad Bioscience
- Novartis
- Novellus Biopharma
- NovellusDx
- Novellus Therapeutics
- Novome Biotechnologies
- Novo Nordisk
- Nrgene
- Nucelis
- Nuvisan Pharma Services
- Obsidian Therapeutics
- ONK Therapeutics
- Ono Pharmaceutical
- Oregon Health Sciences University
- Origin Agritech
- Orna Therapeutics
- Orum Therapeutics
- Otsuka
- Oxford Genetics
- Oxford Nanopore Technologies
- Pairwise Plants
- Parent Project Muscular Dystrophy
- Paul Ehrlich Institute
- Pfizer
- PhenoVista Biosciences
- Pioneer Hi-Bred
- PlantArcBio
- Plant Bioscience Limited
- Pluristem Therapeutics
- Pluristyx
- Poseida Therapeutics
- Precision BioSciences
- Predictive Oncology
- Prevail Therapeutics
- Prime Medicine
- ProBioGen
- Profluent Bio
- Promega
- Pro Pharmaceuticals
- Proventus Bio
- Qihan Biotech
- Qkine
- ReCode Therapeutics
- Regeneron Pharmaceuticals
- ReNAgade Therapeutics
- Repare Therapeutics
- Rett Syndrome Research Trust
- Revvity
- Ricoh
- Roche
- Roche Diagnostics
- Roivant Sciences
- Rokline Health Concepts
- Rosetta Biosciences
- Rutgers University
- Rznomics
- Saint Louis University
- Sana Biotechnology
- Sangamo Therapeutics
- Sanofi
- San Raffaele Scientific Institute
- Santa Cruz Biotechnology
- Sarepta Therapeutics
- SCM Pharma
- Scribe Therapeutics
- Seamless Therapeutics
- Seattle Childrens Research Institute
- Selecta Biosciences
- SeQure Dx
- Setsuro Tech
- Shape Therapeutics
- Shenzhen Salubris Pharmaceuticals
- Sherlock Biosciences
- Shoreline Biosciences
- Sigma-Aldrich
- SiSaf
- Sohm
- SparingVision
- Sphere Fluidics
- Stanford University
- Stanford University School of Medicine
- StemSight
- StrideBio
- Sumitomo Pharmaceuticals
- Synbal
- Syngene International
- Syngenta
- Syngulon
- Synthego
- Taconic Biosciences
- Takara Bio USA
- Takeda Pharmaceutical
- Takeda Ventures
- Tango Therapeutics
- Target ALS Foundation
- TargetGene Biotechnologies
- TCR2 Therapeutics
- Telesis Bio
- The Human Protein Atlas
- The New York Stem Cell Foundation
- Theragent
- Thomas Jefferson University
- Thrive Bioscience
- Tolo Biotech
- Toolgen
- TransCode Therapeutics
- Transomic Technologies
- Tropic Biosciences
- Twist Bioscience
- Ulster University
- Universal Cells
- University of Alabama
- University of Alabama at Birmingham
- University of Arkansas
- University of British Columbia
- University of California
- Davis
- University of California Berkeley
- University of California Los Angeles
- University of California San Francisco
- University of Colorado
- University of Colorado Denver
- University of Edinburgh
- University of Freiburg
- University of Illinois
- University of Iowa
- University of Kansas
- University of Massachusetts
- University of Massachusetts Medical School
- University of Minnesota
- University of Montreal
- University of Nebraska
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Texas
- University of Texas Southwestern Medical Center
- University of Tokyo
- University of Utah
- University of Washington
- University of Wisconsin
- University of Wisconsin-Madison
- US Department of Agriculture
- Vectalys
- Ventana Medical Systems
- Vertex Pharmaceuticals
- Verve Therapeutics
- Vesigen Therapeutics
- Viatris
- VIB
- Vir Biotechnology
- Virginia Commonwealth University
- Vita Therapeutics
- ViVerita Therapeutics
- Vivlion
- Vor Biopharma
- Voyager Therapeutics
- Wageningen University
- Wake Forest University
- Washington University in St Louis
- Watchmaker Genomics
- Weill Cornell Medical College
- Whitehead Institute
- Willow Biosciences
- Yale School of Medicine
- Yale University
- Yield10 Bioscience
- YolTech Therapeutics
- ZeClinics
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
